Pfanstiehl has launched a new cGMP-produced, parenteral-grade maltose for pharmaceutical formulations. The excipient is a new high purity, low endotoxin, maltose (USP/NF, EP, JP), manufactured in the US under cGMP, ICH Q7 compliant conditions. Maltose is a multifunctional disaccharide used to stabilize protein therapeutics, intravenous IG infusions, and as a bioprocessing aid.

Maltose has shown an ability to prevent aggregation in IVIG solutions and to act as a bulking agent in final formulations. and is an option, along with other carbohydrates, such as trehalose, sucrose, and sorbitol when developing platforms for stabilizing monoclonal antibodies, antibody drug conjugates, and vaccines.

Also, the company has launched a cGMP-produced, parenteral-grade ribose for pharmaceutical applications. Ribose is a monosaccharide, and the product is a high-purity, low-endotoxin, ribose (USP/NF, EP, JP), manufactured in the US under cGMP, ICH Q7 compliant conditions.

Source: Pfanstiehl (maltose) and Pfanstiehl (ribose)